CRISPR Therapeutics
NEWS
Exo Therapeutics’ approach is not only different, it has revolutionary potential.
It was a relatively quiet week for clinical trial announcements. Here’s a look.
CRISPR Therapeutics and ViaCyte dosed their first patient in Phase I clinical trial of a novel gene-edited cell replacement therapy to treat Type 1 Diabetes.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Sangamo Therapeutics announced that Sanofi US was returning its rights to SAR445136 as it shifts its approach from personalized cell therapies to allogeneic off-the-shelf genomic approaches.
Biopharma and life sciences companies from across the globe provide updates. Belgium-based Galapagos NV won European approval for Jyseleca for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
This year’s top 30 large and small companies operate in some of the Life Sciences’ hottest spaces – precision medicine, vaccines, gene editing, genomics and oncology.
Clade Therapeutics will use its funds to further its research and development on cancer treatments, while GRO Biosciences will focus on chronic diseases.
It was yet another busy week for clinical trial announcements. Take a look.
JOBS
IN THE PRESS